相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
Naoki Horikawa et al.
BRITISH JOURNAL OF CANCER (2020)
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Qian Li et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Xinrong Wang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Neutrophil plasticity in the tumor microenvironment
Morgan A. Giese et al.
BLOOD (2019)
PD-1/PD-L1 blockade rescue exhausted CD8+T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
Rui Zhao et al.
CELL PROLIFERATION (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Neutrophil Degranulation, Plasticity, and Cancer Metastasis
Faustino Mollinedo
TRENDS IN IMMUNOLOGY (2019)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Emerging role of PI3K/AKT in tumor-related epigenetic regulation
Qi Yang et al.
SEMINARS IN CANCER BIOLOGY (2019)
Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth
Jiahao Zhang et al.
REDOX BIOLOGY (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
Tumour-associated neutrophils in patients with cancer
Merav E. Shaul et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Bruno Silva-Santos et al.
NATURE REVIEWS CANCER (2019)
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
Hideki Iwamoto et al.
CELL METABOLISM (2018)
Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines
Xiuju Chen et al.
CELLULAR IMMUNOLOGY (2018)
PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment
Xiaoyan Liu et al.
FUTURE ONCOLOGY (2018)
OX40L induces helper T cell differentiation during cell immunity of asthma through PI3K/AKT and P38 MAPK signaling pathway
Li Huang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The role and significance of VEGFR2+ regulatory T cells in tumor immunity
Panrong Zhu et al.
ONCOTARGETS AND THERAPY (2017)
Microenvironmental regulation of tumour angiogenesis
Michele de Palma et al.
NATURE REVIEWS CANCER (2017)
γδ T Cells: Unexpected Regulators of Cancer Development and Progression
Christopher Fleming et al.
TRENDS IN CANCER (2017)
Neutrophils in the Tumor Microenvironment
Davalyn R. Powell et al.
TRENDS IN IMMUNOLOGY (2016)
Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs
Merav E. Shaul et al.
ONCOIMMUNOLOGY (2016)
Hypoxia-recruited angiogenic neutrophils
Eric L. Campbell
BLOOD (2015)
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Seth B. Coffelt et al.
NATURE (2015)
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Lee B. Rivera et al.
CELL REPORTS (2015)
γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer
Pin Wu et al.
IMMUNITY (2014)
Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties
Francoise Bono et al.
CANCER CELL (2013)
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Yuhui Huang et al.
CANCER RESEARCH (2013)
The origin and fate of γδT cell subsets
Jan Kisielow et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
Apostolos C. Ziogas et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Annamaria Rapisarda et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Forty-Year Journey of Angiogenesis Translational Research
Yihai Cao et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
Refractoriness to antivascular endothelial growth factor treatment: Role of myeloid cells
Farbod Shojaei et al.
CANCER RESEARCH (2008)
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies
Farbod Shojaei et al.
DRUG RESISTANCE UPDATES (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G Bocci et al.
CANCER RESEARCH (2004)
分享论文
